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Abstract
Among patients with cardiovascular disease (CVD), depression is highly prevalent and is
associated with worse cardiovascular prognosis and lower quality of life. Treatments for
depression in CVD patients produce modest, but clinically significant reductions in depressive
symptoms and show promise for improving cardiovascular prognosis. While tricyclics should
generally be avoided, antidepressants from multiple other classes appear to be safe in cardiac
patients. A strategy of engaging patients in choosing medications or psychotherapy and then
intensifying treatment to therapeutic goal appears to be more effective at reducing depression than
single mode interventions. Recommendations for screening all CVD patients for depression may
be premature given increased costs associated with screening and gaps in knowledge about the
risk-benefit ratio of depression treatment in mild and moderately depressed patients.
Introduction
Patients with cardiovascular disease (CVD) have a two-fold increased risk of depression
compared to patients without heart disease.1 Moreover, the presence of depression in CVD
patients is associated with increased mortality, cardiac events, and health care costs, as well
as lower quality of life and adherence to recommended treatments.2 Given the high impact
of comorbid depression on medical, quality of life, and societal outcomes in patients with
CVD, a growing body of research has assessed the effectiveness of depression interventions
in these patients. While a tantalizing goal of depression treatment is the possibility that it
might improve cardiovascular prognosis, the remission of depression, alone, is a worthy goal
of depression treatment as depression is a major contributor to lower quality of life and
increased health care costs in CVD patients.
Before evaluating the effectiveness of depression treatments in CVD patients, it is important
to consider why treatment of depression in such patients may differ from treatment of
depression in the general population. First, there is heightened concern regarding the
possibility for cardiotoxic effects of some depression treatments. Second, if the depressive
symptoms are in reaction to the stressful medical event (e.g. an adjustment disorder in
reaction to the CVD event), then the symptoms are likely to spontaneously remit without
screening and treatment. Third, the acceptability of a psychiatric treatment may differ in
patients for whom CVD is the primary disease. Fourth, although mild sub-syndromal
symptoms of depression have been associated with worse prognosis in CVD patients, it is
not clear whether standard depression treatments will benefit CVD patients with milder
depressive symptom burden. With these considerations in mind, below we review the
evidence behind single modality and combined interventions involving pharmacotherapy,
psychotherapy, or other approaches to treating depression in CVD patients.(Table 1)
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Concern about the safety of antidepressant medications in cardiac patients emerged from the
experience gained from the Cardiac Arrhythmia Suppression Trial (CAST) in which post-
myocardial infarction (MI) patients treated with Class 1 antiarrhythmics had increased
mortality. Because tricyclic antidepressants belong to the group of Class 1a antiarryhthmics,
tricyclic antidepressants are presumed to be unsafe for use in depressed patients with
ischemic heart disease.3 Subsequent to CAST, investigators have carefully explored the
safety and benefits of newer generation antidepressants in CVD patients.
The first large-scale trial carefully assessing the safety of serotonin-specific reuptake
inhibitors (SSRIs) in CVD patients was the Sertraline Treatment of Major Depression in
Patients with Acute Myocardial Infarction or Unstable Angina (SADHART).4 In this study,
369 participants with major depressive disorder after MI were randomized to sertraline or
placebo. The primary outcome was change in left ventricular ejection fraction (LVEF) at
four months. SADHART also assessed the effectiveness of sertraline at reducing depressive
symptoms. Sertraline was found to have short-term safety with respect to LVEF as well as
safety for secondary outcomes including blood pressure and ECG characteristics.
Although sertraline demonstrated short-term safety, sertraline did not significantly reduce
depression symptoms in the overall sample according to the primary depression rating scale.
This study, however, was not powered to detect differences in depression symptoms.
Subsequent trials have assessed the effectiveness of other antidepressants in CVD patients.
Antidepressants tested include citalopram (CREATE)5 and mirtazepine (MIND-IT)6, and of
these two, only citalopram resulted in a clear reduction in depression symptoms and increase
in depression remission. A Cochrane meta-analysis of antidepressant trials showed that,
overall, antidepressants produce a small, but clinically significant reduction in depression
symptoms and result in reduced re-hospitalizations for combined cardiac and non-cardiac
diagnoses.7
The Cochrane meta-analysis also examined the effect of antidepressants in depressed CVD
patients on cardiac outcomes and all-cause mortality. The meta-analysis showed that
although antidepressants were associated with lower odds of mortality and recurrent cardiac
events, the confidence intervals for these comparisons crossed 1 such that they did not reach
the predefined significance level.7 A separate meta-analysis that only included trials of SSRI
antidepressants concluded that SSRI use was associated with a significant decrease in CVD
readmission (risk ratio 0.63, 95% CI 0.46 to 0.86) and mortality rates (risk ratio 0.56, 95%
CI 0.35 to 0.88).8 This meta-analysis, however, included data from non-randomized
samples.
Psychotherapy
The largest study of depression treatment in CVD patients is the Enhanced Recovery in
Coronary Heart Disease Patients (ENRICHD) trial.9 This study randomized 2500 post-
myocardial infarction (MI) patients and tested whether enhanced treatment of depression
with cognitive behavioral therapy (augmented by sertraline for treatment non-responders)
could improve both depression and event-free survival. While the intervention significantly
decreased depressive symptoms, there were no significant differences in all-cause mortality
or MI recurrence between the intervention and usual care arms. Subgroup analysis showed
that while there was a trend toward benefit in men, there was a nearly significant p-value for
harm in women (p < 0.03 for the interaction between arms and gender for MI recurrence/
death). Post-hoc adjustment for age and Charlson comorbidity index attenuated the
interaction considerably (p<0.20), but there is no other sufficiently-powered trial to
determine if this was a chance finding, or if some harm might accrue to female MI patients
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provided with psychological depression treatment. While the results of ENRICHD were a
disappointment to experts in the field of behavioral cardiology, commentators noted that 1)
the cognitive behavioral therapy treatment yielded only modest improvements in depression
with an effect size of 0.31 (typically considered a ‘small’ effect size) and 2) usual depression
care resulted in greater improvements than expected, possibly because some of the
depressed cases had adjustment disorder that spontaneously remitted, and possibly because
participation in the trial led to greater awareness of depression and this improved usual
depression care.
Researchers have subsequently tested other psychological treatments for depression
including interpersonal psychotherapy 5 and supportive stress management.10 These
approaches overall resulted in small benefits in improving depression on the same order of
magnitude as pharmacologic based interventions. No trial of psychological intervention,
alone, has yet been associated with a reduction in cardiovascular outcomes or mortality, but
as mentioned above, only one has had a sufficient number of patients to actually test this
properly.
There are a few examples of head-to-head comparisons between different types of
psychological interventions or between psychological and pharmacologic interventions for
depression treatment in CVD patients.(Figure 1) The Canadian Cardiac Randomized
Evaluation of Antidepressant and Pyschotherapy Efficacy Trial (CREATE) involved a full
factorial design with four arms: citalopram + interpersonal psychotherapy , citalopram +
clinical management, placebo + interpersonal psychotherapy , and placebo + clinical
management. In this trial, citalopram outperformed interpersonal psychotherapy in reducing
depression in patients with stable coronary artery disease. Freedland et al. compared
cognitive behavioral therapy with stress management in post-coronary artery bypass graft
(CABG) patients and found cognitive behavioral therapy more effective.10
Combined approaches
In mental health and primary care settings, evidence suggests that combinations of
psychotherapy and antidepressants are better than either treatment modality alone.
Furthermore, many patients hold preferences for one mode of mental health treatment over
another. For example, while some patients have heightened concerns about side-effects of
antidepressant medications, others are skeptical of the potential for benefitting from
psychotherapy or may lack the time and financial resources to attend multiple psychotherapy
appointments. Accordingly, in an effort to develop more potent depression interventions,
cardiovascular researchers have tested enhanced depression care interventions in which
patients choose their initial treatment modality and then are followed by mental health
specialists who intensify or “step-up” treatment when depression symptoms are not
remitting.11,12 This patient-preference, stepped-care approach resulted in a larger depression
treatment effect size in one trial of post-ACS patients (Coronary Psychosocial Evaluation
Study; COPES, effect size 0.59).12 Participants in the intervention group of this study were
all given access to problem solving psychotherapy at no cost. Notably, the COPES
intervention also resulted in a borderline significant short-term reduction in recurrent
cardiovascular events (p=0.05).
Other treatments
Exercise is effective at treating depression in the general population. Accordingly, trials are
underway to determine whether exercise can compare favorably with antidepressant
medications for treating depression in cardiac patients13 and there is speculation that such an
approach may also be more effective at improving CVD outcomes. Investigators have also
explored whether alternative depression treatments such as omega-3 fatty acids can help
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increase the effectiveness of antidepressant medications in CVD patients, but found no
benefit of omega-3 fatty acids in one recent placebo-controlled clinical trial.14
Other considerations during depression treatment
Adherence to secondary prevention
One of the mechanisms by which depression is believed to influence CVD prognosis is
through its adverse impact on adherence to secondary prevention behaviors and risk-factor
control. Depressed patients have lower rates of adherence to medications, exercise, smoking
cessation, and cardiac rehabilitation attendance among others.15,16 Enhanced treatment of
depression, alone, may be insufficient for improving adherence behaviors. One study of
CVD patients with depression and comorbid cardiovascular risk factors (systolic blood
pressure, LDL cholesterol) found that simultaneous treatment of both depression and risk
factors to goal with the assistance of collaborative care managers led to improvements in
risk factor control.17 Interestingly, despite improving risk factors and depression, this
approach did not improve adherence to medications and improvements in risk factor control
were attributed to more intensive titration of medications by clinicians.
The role of beta-blockers
Historically, there have been concerns that beta-blockers, a mainstay of secondary
prevention in post-MI patients, cause or exacerbate depression symptoms. Beta-blockers can
be associated with adverse side-effects including fatigue and, in some cases, sexual
dysfunction. However, rigorously conducted, placebo-controlled, studies have since
disproven the conventional wisdom that beta-blockers worsen overall depressive
symptoms.18 While this does not preclude the possibility that certain individuals are
susceptible to rare depressogenic side-effects of beta-blockers, this class of drug should not
be denied to depressed patients for this reason. Instead, careful attention should be paid to
ensuring that depressed patients are using all available evidence-based risk-reducing
pharmacologic treatments since these patients are at elevated risk for cardiac events.
Unanswered Questions
Who are the optimal patients to target for enhanced depression treatment?
Existent trials of depression treatments have used a heterogeneous set of eligibility criteria,
both in terms of the nature of CVD (acute versus stable) and with respect to the severity and
timing of depression symptoms. Elevated depressive symptoms frequently remit without
treatment after hospitalization for ACS. Hence, targeting depression treatments at persistent,
rather than remittent, depressed patients may lead to greater relative benefits. Further, in
non-cardiac populations, there is evidence that antidepressant medications are only effective
in patients with severe depressive symptoms. Hence, while even mild depressive symptoms
confer increased risk in CVD patients, novel interventions may be needed to reduce this type
of milder depression in CVD patients. Depression is a heterogeneous condition comprised of
both somatic and psychological symptoms. There is data demonstrating that patients with
anhedonic (lack interest or pleasure in doing things), but not depressive symptoms have
increased risk for poor cardiac outcomes.19 Hence, targeting anhedonic depression may be
more effective at improving cardiovascular prognosis. Finally, some studies have shown that
patients with first-onset of depression after acute coronary events are at especially high risk
for poor subsequent prognosis.20 This may represent an important group of depressed CVD
patients to target in future studies.
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Should all CVD patients be screened for depression?
Despite the extensive epidemiology connecting depression and poor prognosis in CVD
patients, recent surveys have shown that many cardiologists are unaware of the
epidemiology associating depression and CVD and even fewer screen or treat depression.21
Accordingly, several professional societies including the American Association of Family
Physicians and multiple European societies of cardiovascular disease prevention have
published guidelines for the management of depression in CVD patients and, in 2008, the
American Heart Association (AHA) published a science advisory recommending routine
screening for depression in CVD patients.22 This AHA publication led to considerable
controversy by leaders in the field. On the one hand, proponents argued that depression
screening when tied to depression care management programs is already evidence-based for
primary care and can be assessed with as few as two questions. Proponents further argued
that depression treatments appear to be safe and similarly effective at reducing depression in
CVD patients as compared to the general population, and may potentially improve
prognosis. Others, however, are concerned that there is insufficient information to
recommend depression screening.23 Many patients identified through screening will have
mild symptoms that are unlikely to benefit from current treatments and which may
spontaneously remit. Further, while depression treatments appear to be safe, there was a
trend toward harm from psychological treatment among women in ENRICHD and the long-
term consequences of newer generation antidepressants in CVD patients remain poorly
understood. Those opposed to universal screening point out that while screening may be
brief, the consequences of screening may consume significant health care resources with
unclear benefits.24
Summary and recommendations for treating depression in CVD patients
A variety of depression treatments are effective in depressed CVD patients. Although there
is a need to develop more potent depression interventions for CVD patients, the effect size
of such treatments with respect to reducing depression is similar in CVD patients as
compared to the general population. (Figure 2) Other than one trial for which the effect of
the intervention on prognosis was a secondary outcome12, depression treatment has not thus
far been proven to offset the risk of depression on cardiovascular prognosis. However, only
one trial of depression treatment has been adequately powered to assess this outcome, and
when analyzed together, depression interventions show promise for being able to not only
reduce depression, but reduce major adverse cardiac events and mortality as well.(Figure 3)
Accordingly, there is a need for additional trials of our most potent depression interventions
in CVD patients.
Until these definitive trials have been performed, patients who present with symptoms or
signs of depression should be carefully interviewed to assess for the severity of symptoms
and the risk of suicide.(Figure 4) Clinicians can also consider screening all CVD patients for
depression, however current evidence has not verified that this is a cost-effective approach.
Structured depression assessment tools like the Patient Health Questionnaire-9, comprised of
9 items that ask about the frequency of symptoms used to diagnose depression according to
the Diagnostic and Statistical Manual (DSM-IV) classification system, can be useful
supplements to clinical interviews. In addition, serial measurements of depression severity
using such tools can be helpful for tracking the effectiveness of depression treatments.
Patients with minimal symptoms can be observed with a plan to re-assess symptoms at a
later date. In contrast, patients with severe symptoms or at risk for suicide should be
urgently assessed by a mental health specialist. Patients with mild to moderate symptoms
should be educated about treatment options and should then be asked for their preferred
approach. Unless patients have severe symptoms or are at risk for suicide, observation with
scheduled follow-up remains a reasonable option as depression symptoms may
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spontaneously remit especially if they developed after acute coronary events. Clinicians will
benefit by being informed as to the availability and affordability of treatment options in their
health care system, especially non-pharmacologic ones. Ideally, clinicians will have
identified mental health specialists or collaborative care managers with expertise in
managing patients with comorbid depression and CVD. With patient preferences in mind,
patients can then be referred to appropriate specialists and/or antidepressants can be initiated
by the treating provider. Close collaboration with mental health specialists or other members
of the treatment team will be important to ensure that depression treatment is optimized.
Clinicians should be cautioned that these recommendations are opinion-based, and not
evidence-based, as neither a depression screening or CVD outcome randomized trial has
been performed yet to directly inform clinical practice.
Other than ensuring that depressed patients are receiving appropriate depression treatment,
clinicians should pay special attention to risk factor control and to adherence problems. The
use of non-judgmental language during adherence assessments and possibly, validated
adherence assessment tools such as the Morisky Medication Adherence Questionnaire, may
facilitate more accurate adherence assessments.
Acknowledgments
Dr. Kronish is funded by grant K23HL098359 from the National Heart, Lung, and Blood Institute
References
1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients
with coronary heart disease: a meta-analysis. Psychosom Med. 2004; 66:802–13. [PubMed:
15564343]
2. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following
myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med.
2004; 66:814–22. [PubMed: 15564344]
3. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients.
Risk-benefit reconsidered. JAMA. 1993; 269:2673–5. [PubMed: 8487453]
4. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients
with acute MI or unstable angina. JAMA. 2002; 288:701–9. [PubMed: 12169073]
5. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal
psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac
Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA.
2007; 297:367–79. [PubMed: 17244833]
6. Honig A, Kuyper AM, Schene AH, et al. Treatment of post-myocardial infarction depressive
disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007; 69:606–
13. [PubMed: 17846258]
7. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression
in patients with coronary artery disease. Cochrane Database Syst Rev. 2011; 9:CD008012.
[PubMed: 21901717]
8. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective
serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol.
2011; 107:972–9. [PubMed: 21256471]
9. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social
support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart
Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003; 289:3106–16. [PubMed: 12813116]
10. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass
surgery: a randomized controlled trial. Arch Gen Psychiatry. 2009; 66:387–96. [PubMed:
19349308]
Kronish et al. Page 6













11. Rollman BL, Belnap BH, LeMenager MS, et al. Telephone-delivered collaborative care for treating
post-CABG depression: a randomized controlled trial. JAMA. 2009; 302:2095–103. [PubMed:
19918088]
12. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute
coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies
randomized controlled trial. Arch Intern Med. 2010; 170:600–8. [PubMed: 20386003]
13. Blumenthal JA, Sherwood A, Rogers SD, et al. Understanding prognostic benefits of exercise and
antidepressant therapy for persons with depression and heart disease: the UPBEAT study--
rationale, design, and methodological issues. Clin Trials. 2007; 4:548–59. [PubMed: 17942470]
14. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3
augmentation of sertraline in treatment of depression in patients with coronary heart disease: a
randomized controlled trial. JAMA. 2009; 302:1651–7. [PubMed: 19843899]
15. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with
coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005;
165:2508–13. [PubMed: 16314548]
16. Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects adherence to secondary
prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006; 21:1178–83.
[PubMed: 16899061]
17. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic
illnesses. N Engl J Med. 2010; 363:2611–20. [PubMed: 21190455]
18. van Melle JP, Verbeek DE, van den Berg MP, Ormel J, van der Linde MR, de Jonge P. Beta-
blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll
Cardiol. 2006; 48:2209–14. [PubMed: 17161247]
19. Davidson KW, Burg MM, Kronish IM, et al. Association of anhedonia with recurrent major
adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry.
2010; 67:480–8. [PubMed: 20439829]
20. Parker GB, Hilton TM, Walsh WF, et al. Timing is everything: the onset of depression and acute
coronary syndrome outcome. Biol Psychiatry. 2008; 64:660–6. [PubMed: 18602090]
21. Feinstein RE, Blumenfield M, Orlowski B, Frishman WH, Ovanessian S. A national survey of
cardiovascular physicians’ beliefs and clinical care practices when diagnosing and treating
depression in patients with cardiovascular disease. Cardiol Rev. 2006; 14:164–9. [PubMed:
16788327]
22. Lichtman JH, Bigger JT Jr. Blumenthal JA, et al. Depression and coronary heart disease:
recommendations for screening, referral, and treatment: a science advisory from the American
Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on
Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on
Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association.
Circulation. 2008; 118:1768–75. [PubMed: 18824640]
23. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in
cardiovascular care: a systematic review. JAMA. 2008; 300:2161–71. [PubMed: 19001627]
24. Ziegelstein RC, Thombs BD, Coyne JC, de Jonge P. Routine screening for depression in patients
with coronary heart disease never mind. J Am Coll Cardiol. 2009; 54:886–90. [PubMed:
19712796]
25. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of
antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358:252–60.
[PubMed: 18199864]
Kronish et al. Page 7














Comparison of effect sizes of depression treatments on depression outcomes in patients with
cardiovascular disease.
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The effect sizes of pharmacotherapy for depression are similar in trials of patients with
cardiovascular disease as compared to the general population. The estimate for the effect
size of antidepressants in the general population is based on a systematic review of 125
published and unpublished trials.25
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Comparison of effects sizes of depression treatments on cardiovascular outcomes and/or all-
cause mortality in patients with cardiovascular disease
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Algorithm for managing depression in patients with cardiovascular disease
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Table 1
Summary of key trials of depression treatment in patients with cardiovascular disease
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